Novo Nordisk has built a real new business in a pill. Oral Wegovy holds roughly 90 percent of the US oral-obesity market, its cumulative American prescriptions have passed five million since launch, and it filled more than 265,000 scripts in a single week this July. By the measures investors usually cheer, the launch is a runaway. Then comes the dollar reality: in the second quarter the pill sold DKK 3.2 billion, about $494 million, and still missed the analyst consensus that had called for DKK 3.6 billion. Volume leadership that does not yet convert into revenue leadership.
Ninety percent of the class, short on the quarter
That gap is the whole story, and it is not a demand story. The instinct with any "new opportunity" is to ask whether a scarce, hard-to-replicate product can name its own price. The evidence here says no. The pill is a real revenue stream with high absolute margins; it just is not collecting scarcity rent. It earns by volume.
The starter dose shows where the price leaks out. Of roughly 721,000 US prescriptions tracked in the first quarter, about 450,000 of them — almost two-thirds — were for the cheapest option, the 1.5 mg dose at $149 a month. That concentration sits on the price floor. BMO Capital Markets estimated first-quarter pill revenue landed roughly 12 percent below a consensus of about $1 billion. Wall Street itself frames the backdrop as a "bruising price war" in obesity drugs, and here the fight is visible inside the launch mix, not just in the headlines.
That is why the economics of this class turn on one machine rather than on a moat. Prescription growth has to outrun a realized net price that keeps sliding as starter-volume snowballs and rebates mount. If volume wins the race, the pill adds revenue and, inside Novo's ~78 percent company gross margin, meaningful incremental profit. If price slides faster, the class adds gross sales without transferring any pricing power to NovoNVO-- — and the whole point of a tollbooth investment, that you get paid for being necessary, quietly disappears.
A real class, now a shared one
Novo does not even get to run the race alone. Lilly's rival oral pill Foundayo won US approval in early April 2026, closing the window when Novo was the only oral obesity option. Brokerages already project Foundayo sales of $1.5 billion to $2.8 billion this year, with J.P. Morgan seeing about $6 billion by 2027; UBS puts Novo and Lilly together at roughly $5 billion for the combined oral class in 2026. That is the truth about the opportunity in one line: it is a large new class, but a shared one, and the sharing started before the first rival quarter even mattered.
None of this makes the pill a money-loser, and that is worth being precise about. Novo's second-quarter gross margin was about 78.2 percent and its operating margin about 42.5 percent, with adjusted operating profit up 11 percent at constant exchange rates. So the company is defending high absolute rent even as realized prices slip. The pill adds high-margin revenue through volume. The danger is reading that margin and concluding the pill holds pricing power — high margin per unit and declining price per script are different claims, and only the first is true here.
Then run the class against the company it belongs to. Novo guided full-year 2026 adjusted sales growth at constant exchange rates to between flat and down 6 percent — a revision upward from an earlier expectation of a 4 to 12 percent decline, but still a declining outlook. A new multi-billion-dollar opportunity, three quarters into its US launch, and consolidated revenue is still expected to shrink. That is the cleanest measure of how little the pill moves the whole company: it is high-margin volume stacked on top of a business that remains in retreat.
The market has already absorbed the shape of this. Novo trades at a trailing price-to-earnings ratio around 10.6, against Lilly's roughly 40, per Ainvest data — the share price is not paying for a solo-pill scarcity window. It is paying for a volume story, which means its value depends on prescriptions outpacing declining realized prices, not on a tollbooth nobody else can build.
So the pill is worth real money — it is just not a pricing-power windfall. Its value rests entirely on the volume-versus-price race. The confirmation to watch is whether the mix starts crowding off the $149 starter dose onto higher-priced maintenance doses: if weekly starts keep climbing while the share stuck on 1.5 mg stays high, the volume-to-price trade is not improving, and the incremental margin stays soft no matter how many scripts arrive. The signal that this becomes an ordinary story instead of a growing one is the same machine running backward — net realized price per script falling faster than prescription growth for a couple of quarters. Until then, the pill is what it looks like: a high-margin business that wins on count, and a pricing story that simply never shows up.
Comments
No comments yet